The effect of glucagon-like peptide 1 on cardiovascular risk
Research output: Contribution to journal › Journal article › Research › peer-review
Jacob Sivertsen, Jaya Rosenmeier, Jens Juul Holst, Tina Vilsbøll
Glucagon-like peptide 1 (GLP-1) is an incretin hormone responsible for amplification of insulin secretion when nutrients are given orally, as opposed to intravenously, and it retains its insulinotropic activity in patients with type 2 diabetes mellitus. GLP-1-based therapies, such as GLP-1 receptor agonists and inhibitors of dipeptidyl peptidase 4, an enzyme that degrades endogenous GLP-1, have established effectiveness in lowering glucose levels and are routinely used to treat patients with type 2 diabetes. These agents regulate glucose metabolism through multiple mechanisms and have several effects on cardiovascular parameters. These effects, possibly independent of the glucose-lowering activity, include changes in blood pressure, endothelial function, body weight, cardiac metabolism, lipid metabolism, left ventricular function, atherosclerosis, and the response to ischemia-reperfusion injury. Thus, GLP-1-based therapies could potentially target both diabetes and cardiovascular disease. This Review highlights the mechanisms targeted by GLP-1-based therapies, and emphasizes current developments in incretin research that are relevant to cardiovascular risk and disease, as well as treatment with GLP-1 receptor agonists.
|Journal||Nature Reviews Cardiology|
|Number of pages||14|
|Publication status||Published - Apr 2012|
- Animals, Blood Glucose, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Evidence-Based Medicine, Glucagon-Like Peptide 1, Humans, Hypoglycemic Agents, Receptors, Glucagon, Risk Assessment, Risk Factors, Treatment Outcome